-
Calpeptin and Cell-Death Assay Interpretation
2026-09-23
Calpeptin is a potent calpain inhibitor used in pulmonary fibrosis research, but a change in a fibrosis marker does not by itself reveal what happened to cell survival. This article connects cell-death biology with careful assay interpretation and explains how to evaluate calpain inhibition without overstating the evidence.
-
Annexin V-Cy5 Apoptosis Kit in Microglia
2026-09-23
Use the Annexin V-Cy5 Apoptosis Kit to separate phosphatidylserine-positive cell death from reversible lysosomal stress in microglia models. Its rapid, one-step workflow supports both spatial fluorescence imaging and quantitative flow cytometry apoptosis detection during exposure, washout, and cell-type-specific experiments.
-
PLGA Nano-Adjuvant Enhances Chick Mucosal Immunity
2026-09-22
The reference study develops PEI-LSP-RA-PLGA, a multilayer PLGA nano-adjuvant designed to combine sustained release, intestinal targeting, and coordinated mucosal and systemic immune activation in chicks. Its reported increases in serum IgG and intestinal IgA, together with CCR6/CCR9-associated targeting and Toll-like and NOD-like receptor signaling, provide a mechanistic framework for improving H9N2 vaccine performance.
-
VE-822: Choosing 2D or 3D Radiosensitization Models
2026-09-22
VE-822 is an ATR inhibitor for investigating replication-stress signaling and radiation response. This article explains how recent 2D-versus-3D evidence can guide assay selection, particularly when translating findings into PDAC research.
-
G418 Sulfate: From Selection to Translation
2026-09-21
Geneticin is more than a routine selection reagent. This thought-leadership article connects G418 Sulfate’s ribosomal mechanism and selective pressure with emerging insights into CD8+ T-cell metabolic flexibility, while providing practical guidance for engineered cell lines and antiviral studies. It also defines the limits of translating selection biology into immunometabolic or Dengue research.
-
Enzalutamide Alters Myeloid Tumor Suppression
2026-09-21
The reference study shows that enzalutamide can promote tumor progression by altering AR-expressing myeloid cells, even when tumor-cell androgen receptor signaling is absent. Its integrated genetic, pharmacologic, immune, and metabolic design links AR blockade to impaired adaptive immunity, enhanced MDSC activity, and altered mitochondrial respiration.
-
Ambroxol Targets Nav1.8, TRPV1, and TRPA1
2026-09-20
This study defines a multi-target electrophysiological basis for the topical analgesic activity of ambroxol, identifying stronger inhibition of rat Nav1.8 than human Nav1.8 and additional modulation of human TRPV1 and TRPA1. Its species-aware patch-clamp design helps distinguish sodium-channel block from direct transient receptor potential effects and clarifies how capsaicin-sensitive pathways may be involved in topical pain research.
-
CB2R Modulation of Iron Overload Liver Injury
2026-09-19
Deng and colleagues identify cannabinoid receptor 2 (CB2R) as a regulator of hepatic iron handling in an iron-dextran mouse model. Their central advance is a cell-specific mechanism: CB2R suppresses STAT3/hepcidin signaling in hepatocytes while enhancing Nrf2/FPN1 activity in Kupffer cells, linking improved iron efflux with reduced oxidative and inflammatory injury.
-
CCL7+ Macrophages and CRC Immunotherapy Resistance
2026-09-18
The reference study identifies CCL7-expressing tumor-associated macrophages as an important driver of colorectal cancer resistance to immune checkpoint inhibition. Using myeloid-specific knockout models, MC38 tumors, proteomics, RNA sequencing, and flow cytometry, the authors connect CCL7 to macrophage metabolism and reduced CD8+ T-cell infiltration, providing a rationale for combining CCL7 blockade with anti-PD-L1 therapy.
-
Metabolic Sensitization of Ferroptosis and Cuproptosis
2026-09-18
The 2024 Chemical Engineering Journal study develops SCu/L, a copper–tannic acid network/liposome system carrying STF-31, to inhibit glycolysis and compensatory NAD+ metabolism while increasing tumor-cell susceptibility to ferroptosis and cuproptosis. Its practical significance is the integration of metabolic depletion, copper retention, immunogenic cell death, and tumor immune-microenvironment remodeling in one therapeutic design.
-
ACE and Aminopeptidase Inhibition Re-evaluated
2026-09-17
Tieku and Hooper directly compared metallopeptidase inhibitors across porcine kidney aminopeptidases N, A, and W, revealing that several compounds considered selective had broader or different activity profiles than expected. The study provides a practical framework for separating ACE-directed effects from aminopeptidase off-target activity in cardiovascular and metabolic research.
-
Palonosetron hydrochloride: Assay Workflows
2026-09-17
Palonosetron hydrochloride combines subnanomolar 5-HT3 receptor activity with a useful transporter-inhibition window for receptor pharmacology, cancer research, and renal drug–drug interaction studies. This guide translates those properties into practical cell-based workflows for CINV/RINV research and OCT2/MATE1 testing.
-
Silybin A (N1711) for Reliable Cell Assays
2026-09-16
A practical, scenario-driven guide to using Silybin A (SKU N1711) in viability, proliferation, and cytotoxicity workflows. It covers solvent control, assay interference, dose design, endpoint interpretation, and vendor selection using product specifications and relevant literature.
-
Chloramphenicol: A Rigorous Plasmid Assay Lens
2026-09-16
Chloramphenicol is more than a selection antibiotic: it can help separate plasmid maintenance, resistance phenotype, and gene transfer in molecular biology assays. This article connects the A2512 reagent to the 2025 Guangdong CREC study while emphasizing controls, orthogonal validation, and the limits of cross-domain interpretation.
-
MK-2206 Dihydrochloride: Akt Pathway Guide
2026-09-15
MK-2206 dihydrochloride is a selective allosteric inhibitor of Akt1, Akt2, and Akt3 that suppresses Akt phosphorylation at Thr308 and Ser473. Product information supports its use in cancer cell apoptosis, apoptosis assays, and PI3K/Akt/mTOR pathway studies, while disease-specific applications require independent validation.